menu
    • menu
    [{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Avalon BioVentures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"ART5803","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arialys Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Arialys Therapeutics \/ Avalon BioVentures","highestDevelopmentStatusID":"4","companyTruncated":"Arialys Therapeutics \/ Avalon BioVentures"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ART5803","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Arialys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arialys Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Arialys Therapeutics

    Menu

    Arialys Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arialys Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Arialys Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ART5803

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arialys Starts Dosing in Phase 1 of ART5803 for Autoimmune Neuropsychiatric Diseases

                            Details : ART5803 is a NMDA receptor modulator, antibody drug candidate, which is being evaluated for the treatment of autoimmune neuropsychiatric diseases.

                            Brand Name : ART5803

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 10, 2024

                            Lead Product(s) : ART5803

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arialys Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Arialys Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ART5803

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Avalon BioVentures

                            Deal Size : $58.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatr...

                            Details : The proceeds of the financing will be used to advance new precision medicines that specifically block pathogenic autoantibodies in the central nervous system (CNS), including ART5803, for the treatment of anti-NMDA receptor encephalitis (ANRE) and autoim...

                            Brand Name : ART5803

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 12, 2023

                            Lead Product(s) : ART5803

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Avalon BioVentures

                            Deal Size : $58.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth